Explore the Agenda
8:00 am Check-In & Light Breakfast
8:50 am Chair’s Opening Remarks
Identifying Differentiated Targets & Multispecific Strategies Through Functional Characterisation to Improve Efficacy & Reduce Risk
9:00 am Addressing Solid Tumour Heterogeneity: TROCEPT-Mediated Activation of a Universal Bispecific T-cell Engager via IV Delivery
- Targeting tumour heterogeneity by focusing on markers expressed across all cancer cells, ensuring no malignant cell is missed
- Overcoming immune suppression with therapies potent enough to activate immune responses despite the tumour’s inhibitory environment
- Reducing off-target toxicity by restricting therapeutic activity to tumour cells, expanding the therapeutic window for safer treatment
9:30 am From Discovery to Differentiation: A High-Throughput TCR Discovery Platform Powering Next-Generation bispecific Therapeutics
- Demonstrating large-scale T-cell receptor discovery capability using a proprietary platform that identified hundreds of thousands of TCRs recognising previously uncharacterised antigens
- Validating the discovery-to-development bispecific pipeline by advancing a therapeutic program based on a novel, internally identified target that is distinct from existing programs
- Extending the platform beyond oncology into autoimmune disease by applying the same discovery engine to identify bispecific targets across multiple therapeutic indications
10:00 am Fireside Chat: Beyond PD-1xVEGF- What’s Next for Bispecifics, Emerging Modalities & Non-Oncology Applications?
- Which novel targets and multispecific formats, including bispecific ADCs, could reshape the bispecific and TCE landscape over the next decade, in oncology and beyond?
- As companies move past conventional antibody bispecifics, which strategies or modalities show the most promise for sustained clinical impact, particularly in chronic dosing and non-oncology settings?
- What does multi-targeting enable biologically, and when does added complexity translate into real functional or clinical benefit in long-term and non-oncology treatment paradigms?
- Which early clinical or translational lessons are shaping target selection, modality choice, trial design, and dosing strategies for next-generation multispecifics across oncology and non-oncology indications?
10:30 am Morning Break & Networking
11:00 am Optimising Multispecific Antibody Design for Therapeutic Application
- By incorporating multifunctionality into a single molecule and leveraging novel mechanisms of biological activity, multispecific antibodies have the potential to provide modes of therapeutic intervention not feasible with traditional monoclonal antibodies or their combination
- Imperative to the design of multispecifics however is the optimal integration of each individual binding component within the multispecific structure to yield optimal biological activity, while maintaining desired pharmacological and manufacturing properties. The Azymetric platform, provides a convenient solution for generating efficient stable heterodimer antibody assembly to enable a multispecific platform adaptable to different formats supporting a range of applications
- Case studies covering examples of Azymetric based therapeutics will be shared ranging from Ziihera, approved for the treatment of HER2+ Billiary Tract cancer, to bispecific ADCs, to next generation T-cell engagers incorporating conditional costimulation applicable across solid and hematological cancers. Emphasis will be placed on the importance of matching format to desired biological activity and mode of therapeutic intervention to yield differentiated drug candidates.
11:30 am Preclinical Safety Assessment of Dual ‘AND’ TCEs: Challenges in Selecting Good Target Pairs
- Preclinical development of a dual-targeting T-cell Engager (TCE) – AMG 305
- Leveraging different techniques in a weight of evidence (WoE) approach to uncover target co-localisation in normal human tissues
- Challenges with relevant species determination for AND-gated targets
Maximising Bispecific ADC & Next-Generation Bispecific Therapeutic Impact by Optimising Conjugation, Targeting & Dosing Strategies
12:00 pm Designing Anti-Cytokine Trispecific Antibodies: Strategies for Efficacy, Developability & Clinical Success
- Navigating design considerations when adding third and fourth targets while maintaining structural integrity and functionality
- Balancing potency, safety, and pharmacokinetics in increasingly complex multispecific molecules
- Establishing developable and well-behaved multi-specific molecules
12:30 pm Engineering Complexity with Precision: Designing Next-Generation Bispecific ADCs for Solid Tumour Impact
- Moving beyond binary gating: Fine-tuned molecular engineering of bispecific ADCs novel synergy between targets to achieve precise and effective cancer treatment
- Leveraging modular platforms for generation of complex biologics (including bispecific ADCs) to control geometry, valency, and site-specific conjugation, enabling unbiased hypothesis generation and rapid prototyping of complex drug candidates
- Advancing solid tumour programs while remaining adaptable to emerging indications and modalities
1:00 pm Lunch Break & Networking
2:00 pm Engineering Functional Bispecific Cytokine Agonists: Comparing Antibody–Cytokine Fusions & VHH-Derived Agonist Bispecifics
- Reframing cytokines by attenuation of potency and cis activation
- Contrasting antibody cytokine fusions versus VHH-based strategies to highlight key trade-offs in potency, receptor geometry, selectivity, and safety
- Optimising on-target immune agonism through rational format and engineering choices to maximise efficacy while minimising systemic toxicity
2:30 pm Surface Protein Proximity Mapping Enables Logic-Gated Multispecifics for Safer, More Effective Cancer Therapies
- Identifying proximal proteins on the cancer cell surface through DISCOtech, DISCOs proprietary surfaceome proteomics platform
- Leveraging DISCOtech for target pair discovery and multispecific drug development, allowing the combination of novel, proximal cancer target pairs that are mutually exclusive expressed on normal tissue
- Designing logic-gated mulitspecific ADCs and T-cell engagers, enabling the creation of ultra-clean, cancer-specific therapies
Expanding the Power of Multispecifics by Widening the Therapeutic Window & Enhancing Clinical Impact
3:00 pm Autoregulated Bispecific Antibodies: Harnessing Built-In Feedback to Improve Safety & Durability
- AutoRegulation (AR) is a modular antibody technology that embeds a negative feedback loop to provide precision control over activity, enhancing activity, reducing toxicity and widening the therapeutic index
- Demonstration of applying AR across indications and modalities using a factor VIII mimetic in haemophilia to mitigate thrombosis risk. AR has also been applied to T-cell engagers for oncology and autoimmunity to control CRS, ICANS and cytopenias and prevent T-cell exhaustion, whilst maintaining efficacy
- Advancing NVG-222, the most mature AutoRegulated T-cell engager into clinic with imminent first-patient dosing, presenting IND-enabling studies that helped inform clinical strategy
3:30 pm MAIT Engagers: A Safer Modality with Large Therapeutic Window for the Treatment of Cancer
- Novelty: Leverage a highly abundant, underexplored T-cell population to expand the therapeutic window and enable safer immune engagement strategies
- Activity in solid tumour: MAIT engagers avoid Treg activation in solid tumours, preventing immune suppression seen with conventional CD3 engagers
- Safety: MAIT engagers uniquely activate MAIT cells and do not cause cytokine release syndrome, at difference to CD3 engagers
4:00 pm Afternoon Break & Networking
4:30 pm Next-Generation Multispecific Antibody Engineering for Patients with Inflammatory Skin Conditions Unresponsive to Dupilumab
- Translate clinical non-response into protein engineering opportunities for precision immunomodulation
- Explore next-generation biologic design strategies to overcome pathway redundancy and therapeutic escape
- Dissect molecular and pathway drivers of incomplete or lost response to dupilumab to identify actionable engineering targets
5:00 pm Tumour-Selective Activation of TNFR via Bispecific Antibody Combination
- Our proprietary k/l bsAb platform allows production of a combination of bsAbs in the same cell and their subsequent purification
- Exploring how bsAbs have been developed to selectively activate TNFR in a tumourassociated antigen (TAA)-dependent manner
- This report investigates whether a combination of bsAbs, pairing TNFR and TAA targeting arms, can further enhance TNFR clustering and activation in the tumour microenvironment